Johnson & Johnson will file a supplemental new drug application (sNDA) for Spravato (esketamine) by the end of the year for the treatment of adults with major depressive disorder who have suicidal intent. Two Phase III clinical trials in the challenging patient population met the primary endpoint of reducing depressive symptoms but missed what could have been an important secondary endpoint, improvement in severity of suicidality.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?